eprintid: 10042276 rev_number: 148 eprint_status: archive userid: 608 dir: disk0/10/04/22/76 datestamp: 2018-02-02 12:08:11 lastmod: 2021-09-19 22:16:39 status_changed: 2018-09-05 13:26:50 type: article metadata_visibility: show creators_name: Montalban, X creators_name: Gold, R creators_name: Thompson, AJ creators_name: Otero-Romero, S creators_name: Amato, MP creators_name: Chandraratna, D creators_name: Clanet, M creators_name: Comi, G creators_name: Derfuss, T creators_name: Fazekas, F creators_name: Hartung, HP creators_name: Havrdova, E creators_name: Hemmer, B creators_name: Kappos, L creators_name: Liblau, R creators_name: Lubetzki, C creators_name: Marcus, E creators_name: Miller, DH creators_name: Olsson, T creators_name: Pilling, S creators_name: Selmaj, K creators_name: Siva, A creators_name: Sorensen, PS creators_name: Sormani, MP creators_name: Thalheim, C creators_name: Wiendl, H creators_name: Zipp, F title: ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis ispublished: pub divisions: UCL divisions: B02 divisions: C07 divisions: D05 divisions: F66 divisions: D07 divisions: F85 divisions: C10 divisions: D17 keywords: GRADE methodology, Multiple sclerosis, disease-modifying therapies, guideline note: This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions. abstract: BACKGROUND: Multiple sclerosis (MS) is a complex disease with new drugs becoming available in the past years. There is a need for a reference tool compiling current data to aid professionals in treatment decisions. OBJECTIVES: To develop an evidence-based clinical practice guideline for the pharmacological treatment of people with MS. METHODS: This guideline has been developed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology and following the updated EAN recommendations. Clinical questions were formulated in Patients-Intervention-Comparator-Outcome (PICO) format and outcomes were prioritized. The quality of evidence was rated into four categories according to the risk of bias. The recommendations with assigned strength (strong and weak) were formulated based on the quality of evidence and the risk-benefit balance. Consensus between the panelists was reached by use of the modified nominal group technique. RESULTS: A total of 10 questions were agreed, encompassing treatment efficacy, response criteria, strategies to address suboptimal response and safety concerns and treatment strategies in MS and pregnancy. The guideline takes into account all disease-modifying drugs approved by the European Medicine Agency (EMA) at the time of publication. A total of 21 recommendations were agreed by the guideline working group after three rounds of consensus. CONCLUSION: The present guideline will enable homogeneity of treatment decisions across Europe. date: 2018-02 date_type: published official_url: http://doi.org/10.1177/1352458517751049 oa_status: green full_text_type: other language: eng primo: open primo_central: open_green article_type_text: Article verified: verified_manual elements_id: 1526312 doi: 10.1177/1352458517751049 lyricists_name: Marcus, Elena lyricists_name: Miller, David lyricists_name: Pilling, Stephen lyricists_name: Thompson, Alan lyricists_id: ECCMA37 lyricists_id: DHMIL08 lyricists_id: SPILL91 lyricists_id: ATHOM52 actors_name: Waragoda Vitharana, Nimal actors_id: NWARR44 actors_role: owner full_text_status: public publication: Multiple Sclerosis Journal volume: 24 number: 2 pagerange: 96-120 event_location: England issn: 1477-0970 citation: Montalban, X; Gold, R; Thompson, AJ; Otero-Romero, S; Amato, MP; Chandraratna, D; Clanet, M; ... Zipp, F; + view all <#> Montalban, X; Gold, R; Thompson, AJ; Otero-Romero, S; Amato, MP; Chandraratna, D; Clanet, M; Comi, G; Derfuss, T; Fazekas, F; Hartung, HP; Havrdova, E; Hemmer, B; Kappos, L; Liblau, R; Lubetzki, C; Marcus, E; Miller, DH; Olsson, T; Pilling, S; Selmaj, K; Siva, A; Sorensen, PS; Sormani, MP; Thalheim, C; Wiendl, H; Zipp, F; - view fewer <#> (2018) ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Multiple Sclerosis Journal , 24 (2) pp. 96-120. 10.1177/1352458517751049 <https://doi.org/10.1177/1352458517751049>. Green open access document_url: https://discovery.ucl.ac.uk/id/eprint/10042276/1/Miller_ECTRIMS_EAN_MS_GL__For_publication.pdf document_url: https://discovery.ucl.ac.uk/id/eprint/10042276/87/Miller_Appendices1-10.pdf document_url: https://discovery.ucl.ac.uk/id/eprint/10042276/81/Miller%20Appendix_11__Register_of_interests%20%283%29.pdf